LL-37
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid peptide that serves as a critical component of the innate immune system. Beyond its direct antimicrobial activity against bacteria, viruses, and fungi, LL-37 functions as an immunomodulatory signaling molecule that bridges innate and adaptive immunity.
Talk with an Aspire clinician about whether LL-37 may be appropriate for your health goals.
Text Us NowThe Human Cathelicidin - Innate Immune Defense Peptide
LL-37 (beginning with two leucine residues, hence the name) is the sole member of the cathelicidin family of antimicrobial peptides in humans. It is produced by cleavage of the precursor protein hCAP-18 (human cationic antimicrobial protein 18 kDa) by the serine protease proteinase 3. LL-37 is expressed by neutrophils, macrophages, epithelial cells of the skin, airways, and gastrointestinal tract, and is also found in wound fluid, sweat, and breast milk. It represents a first line of defense in the body's innate immune response.
Research has revealed that LL-37's biological roles extend far beyond simple microbial killing. It serves as a chemokine, attracting immune cells to sites of infection and injury. It modulates inflammatory responses, promotes angiogenesis (new blood vessel formation), and stimulates wound healing. It neutralizes bacterial endotoxins (LPS), modulates dendritic cell differentiation, and influences adaptive immune responses. Studies have also identified anti-biofilm activity, making it relevant to chronic infections where biofilm formation limits the effectiveness of conventional antibiotics. LL-37 deficiency has been associated with increased susceptibility to infections in various clinical contexts.
Aspire Rejuvenation offers LL-37 through licensed 503A compounding pharmacies for patients with recurrent infections, chronic infectious conditions, immune support needs, or wound healing concerns. Our physicians evaluate each patient's immune status, infection history, and specific clinical situation to determine whether LL-37's unique antimicrobial and immunomodulatory properties are appropriate for their needs.

Proposed Mechanism of Action
LL-37's antimicrobial mechanism relies on its physical and chemical properties. As a cationic amphipathic peptide, it adopts an alpha-helical conformation in the presence of biological membranes. The positively charged face of the helix is attracted to the negatively charged lipopolysaccharides (LPS) and lipoteichoic acids on bacterial membranes - structures not found on mammalian cell membranes (which have neutral phospholipids on their outer leaflet). This electrostatic selectivity allows LL-37 to preferentially target microbial membranes. Upon binding, LL-37 inserts into the lipid bilayer and creates pores through a carpet-like or toroidal pore mechanism, disrupting membrane integrity and causing cell death. This physical mechanism of action makes it difficult for bacteria to develop resistance, unlike conventional antibiotics.
LL-37's immunomodulatory functions are equally important and operate through defined receptor systems. Binding to FPRL1 (formyl peptide receptor-like 1) on immune cells triggers chemotaxis, bringing additional immune defenders to infection sites. Through P2X7 receptor activation, LL-37 can induce IL-1beta release from macrophages, bridging innate and adaptive immunity. It also activates toll-like receptor (TLR) signaling pathways that enhance pathogen recognition. In wound healing contexts, LL-37 promotes keratinocyte and fibroblast migration through EGFR transactivation, stimulates angiogenesis by acting on endothelial cells, and modulates the inflammatory phase of healing to support the transition to proliferative repair. Additionally, LL-37 directly neutralizes bacterial LPS (endotoxin), which can reduce the systemic inflammatory response to bacterial infections.
What LL-37 Is Being Explored For
These are the primary areas where LL-37 has been studied or discussed in the context of peptide therapy. Research depth varies by area.
How LL-37 Is Offered
LL-37 is available through Aspire in the following formulations, all compounded by licensed U.S. 503A pharmacies. Your clinician will recommend the appropriate form based on your goals and treatment plan.
Text our team anytime during business hours.
Monday through Friday, 9:30 AM - 6:00 PM.
We're here to help you understand your options.
How Treatment Works
Peptide therapy at Aspire follows a clinician-guided process. LL-37 is not available for self-prescribing or anonymous purchase.
Often Explored Alongside LL-37
These compounds are frequently discussed in similar clinical contexts or combined in treatment protocols.
LL-37 FAQ
LL-37 is one of the most extensively studied antimicrobial peptides in the literature, with thousands of published papers characterizing its antimicrobial, immunomodulatory, and wound healing properties. Clinical application is growing as understanding of its roles in human immunity continues to expand.
Ready to explore LL-37?
Talk with an Aspire clinician about your goals and whether LL-37 therapy may be appropriate for you.
Text Us Now

